Correction to: Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling.

In the original publication of the article, Table 1 was published with incorrect caption and values. The Table 1 with corrected caption and values is given in this Correction.

Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling.

BACKGROUND: Persistent alopecia (PA) after docetaxel has been recently described. The aim of our study is to establish the incidence and characteristics of PA following adjuvant docetaxel for breast cancer (BC) and to test the ability of scalp cooling in prevention. PATIENTS AND METHODS: BC patients receiving adjuvant chemotherapy followed or not by endocrine therapy (and a control group receiving only endocrine therapy) were interviewed in a single institution at 1.5 to 5 years following primary diagnosis searching for PA. A confirmatory prevalence study was later performed in other two institutions. Finally, a prevention study using prophylactic scalp cooling (PSC) with ELASTO-GEL hypothermia caps in patients receiving adjuvant docetaxel was performed. RESULTS: In the initial prevalence study (492 patients), minor forms of PA (grade 1) were recorded with all chemotherapy regimens and aromatase inhibitors. Patients receiving docetaxel regimens at cumulative dose (CD) ≥ 400 mmg/m2 presented a significantly higher prevalence of grades 1 PA (33-52%) and 2 PA (5-12%). Prevalence of grade 2 PA with docetaxel CD ≥ 400 mmg/m2 was confirmed in two other institutions. Overall, grade 2 PA was seen in 10.06% (95% CI 7.36-13.61) of 358 patients with docetaxel regimens reaching CD ≥ 400 mmg/m2, but not in patients with lower docetaxel CD, other chemotherapy regimens, or endocrine therapy alone. In prevention trial, no grade 2 PA occurred among 116 patients receiving adjuvant docetaxel (≥ 400 mmg/m2) and PSC followed-up after a 96 months median time. PSC was well tolerated. No scalp relapses were seen among 30 patients (22% of all inclusions) having disease relapse. CONCLUSION: Adjuvant treatment with docetaxel (CD ≥ 400 mmg/m2) is associated with a significant rate of grade 2 PA, leading to wearing a wig, in around 10% of patients. This toxicity was completely prevented with scalp cooling. Clinical Trial Reference: NCT00515762.

[Obstruction of the upper urinary tract caused by a malignant retrovesicular schwannoma. Therapeutic strategy]. / Obstrucción del tracto urinario superior causada por un Schwannoma maligno retrovesical. Estrategia terapéutica.

We present a case of malignant Schwannoma (MS) of uncommon, retroperitoneal and retrovesical localization in a 42-year-old male, which provoked bilateral ureteral obstruction as a urological manifestation. We show our therapeutic strategy by means of a schedule of systemic neoadjuvant chemotherapy with vincristine, adriamycin, cyclophosphamide, decarbacine combined with exeresis and urinary continuity reconstruction surgery. We point out that it is a low incidence but highly aggressive tumour and that treatment continues to be local radical excision, whilst chemotherapy probably continues to have little value.

Definitive and adjunctive external irradiation in bladder cancer without radical cystectomy.

The retrospective study of 150 bladder tumor cases from I.P.O. (Madrid) that had received a total dose of 5,000 rads of radiotherapy and a minimum 3-year follow-up without subsequent radical surgery is presented. During 1974-1978 all those cases that complied with the minimum requirements were selected. Radiotherapy effectiveness has not been defined. In this series we report the natural evolution of patients with this final treatment. The fact that invasive bladder tumors will become downstaged following irradiation is well known. The percentage varies from 10-40 percent within a short period of time after radiotherapy. The time of response, the possibility of relapse, the prevention of new tumors and the delay in the evolution and disease progression have not been well established. Thus, we have tried to analyze in our series, the time period of tumor relapse in the superficial tumor group, the influence of radiotherapy, as well as the overall survival. In the advanced tumor group, we have examined the response of the tumor to radiotherapy, its lasting period, and survivals. In clinic, a high number of patients with invasive bladder tumor do not undergo total surgery because of the frequent high surgery risk, old age, patient refusal, or indecision by the surgeon. Sometimes the real aggressiveness of the tumors is not apparent initially, or, at diagnosis, the disease has advanced to a stage that precludes effective surgery. In view of the results of chemotherapy in advanced bladder tumors, definitive radiotherapy in older patients with frequent renal dysfunction can result in frequent control of hematuria as well as tumor regression.(ABSTRACT TRUNCATED AT 250 WORDS)